論文

査読有り 国際誌
2020年4月

Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis.

Anticancer research
  • Teiji Kuzuya
  • ,
  • Masatoshi Ishigami
  • ,
  • Takanori Ito
  • ,
  • Yoji Ishizu
  • ,
  • Takashi Honda
  • ,
  • Tetsuya Ishikawa
  • ,
  • Mitsuhiro Fujishiro

40
4
開始ページ
2283
終了ページ
2290
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.21873/anticanres.14193

BACKGROUND/AIM: We aimed to compare the outcomes between sorafenib and lenvatinib as first-line therapy for advanced hepatocellular carcinoma (HCC) with major portal vein tumor thrombosis (Vp3/4). PATIENTS AND METHODS: This retrospective study enrolled 41 HCC patients with Vp3/4 and Child-Pugh A. RESULTS: The outcomes in the lenvatinib group (n=13) were significantly better than those in the sorafenib group (n=28) [best objective response rate according to the modified Response Evaluation Criteria in Solid Tumors: 53.8% vs. 14.3%; p=0.0193, best disease control rate: 92.3% vs. 35.7%; p=0.0008, median overall survival (OS): not reached vs. 187 days; p=0.0040, respectively]. Lenvatinib treatment was the only significant predictor of better OS and time to tumor progression. No patient needed to discontinue lenvatinib treatment due to drug-related adverse events. CONCLUSION: Compared with sorafenib, lenvatinib treatment for advanced HCC with Vp3/4 may lead to more favorable outcomes.

リンク情報
DOI
https://doi.org/10.21873/anticanres.14193
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32234927
ID情報
  • DOI : 10.21873/anticanres.14193
  • PubMed ID : 32234927

エクスポート
BibTeX RIS